2-arachidonoylglycerol

2-arachidonoylglycerol is a lipid of Glycerolipids (GL) class. 2-arachidonoylglycerol is associated with abnormalities such as Atherosclerosis, Heart Diseases, Inflammatory disorder, Colitis and Peripheral Neuropathy. The involved functions are known as Immunoreactivity, inhibitors, Stimulus, Esthesia and Signal Transduction. 2-arachidonoylglycerol often locates in Back, Presynaptic Terminals, Brain region, Blood and Body tissue. The associated genes with 2-arachidonoylglycerol are ADRBK1 gene, Homologous Gene, MGLL gene, PLA2G4A gene and peptide V. The related lipids are oleoylethanolamide, Lipopolysaccharides, Promega, stearic acid and 1-stearoyl-2-arachidonoylglycerol. The related experimental models are Knock-out.

Cross Reference

Introduction

To understand associated biological information of 2-arachidonoylglycerol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with 2-arachidonoylglycerol?

2-arachidonoylglycerol is suspected in Atherosclerosis, Heart Diseases, Sweet's Syndrome, Colitis, Dehydration, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 2-arachidonoylglycerol

MeSH term MeSH ID Detail
Hepatic Encephalopathy D006501 9 associated lipids
Weight Gain D015430 101 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Glioma D005910 112 associated lipids
Obesity D009765 29 associated lipids
Alzheimer Disease D000544 76 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Nervous System Diseases D009422 37 associated lipids
Brain Edema D001929 20 associated lipids
Starvation D013217 47 associated lipids
Per page 10 20 50 100 | Total 51

PubChem Associated disorders and diseases

What pathways are associated with 2-arachidonoylglycerol

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with 2-arachidonoylglycerol?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with 2-arachidonoylglycerol?

Knock-out

Knock-out are used in the study 'Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.' (Walentiny DM et al., 2015), Knock-out are used in the study 'Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12).' (Navia-Paldanius D et al., 2012) and Knock-out are used in the study 'Metabolic Interplay between Astrocytes and Neurons Regulates Endocannabinoid Action.' (Viader A et al., 2015).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with 2-arachidonoylglycerol

Download all related citations
Per page 10 20 50 100 | Total 1060
Authors Title Published Journal PubMed Link
Waku K [Endogenous cannabinoid receptor ligands--anandamide and 2-arachidonoylglycerol]. 2006 Yakugaku Zasshi pmid:16462096
Guagnini F et al. Neural contractions in colonic strips from patients with diverticular disease: role of endocannabinoids and substance P. 2006 Gut pmid:16423891
D'Argenio G et al. Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. 2006 FASEB J. pmid:16403786
Oka S et al. Suppression by WIN55212-2, a cannabinoid receptor agonist, of inflammatory reactions in mouse ear: Interference with the actions of an endogenous ligand, 2-arachidonoylglycerol. 2006 Eur. J. Pharmacol. pmid:16647054
Melis M et al. Protective activation of the endocannabinoid system during ischemia in dopamine neurons. 2006 Neurobiol. Dis. pmid:16762556
Kurabayashi M et al. 2-Arachidonoylglycerol increases in ischemia-reperfusion injury of the rat liver. 2005 Jan-Feb J Invest Surg pmid:15804949
Hayase T et al. Persistent anxiogenic effects of a single or repeated doses of cocaine and methamphetamine: interactions with endogenous cannabinoid receptor ligands. 2005 Behav Pharmacol pmid:16148444
Sancho R et al. Mechanisms of HIV-1 inhibition by the lipid mediator N-arachidonoyldopamine. 2005 J. Immunol. pmid:16148147
Lauckner JE et al. The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. 2005 Proc. Natl. Acad. Sci. U.S.A. pmid:16365309
Gokoh M et al. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, enhances the adhesion of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes. 2005 FEBS Lett. pmid:16288744
Straiker A and Mackie K Depolarization-induced suppression of excitation in murine autaptic hippocampal neurones. 2005 J. Physiol. (Lond.) pmid:16179366
Iturralde M et al. Characterization of the lipolytic pathways that mediate free fatty acid release during Fas/CD95-induced apoptosis. 2005 Apoptosis pmid:16215685
Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. 2005 Diabetes pmid:16186383
Safo PK and Regehr WG Endocannabinoids control the induction of cerebellar LTD. 2005 Neuron pmid:16301180
Alger BE Endocannabinoid identification in the brain: studies of breakdown lead to breakthrough, and there may be NO hope. 2005 Sci. STKE pmid:16278487
Rademacher DJ et al. Waterborne lead exposure affects brain endocannabinoid content in male but not female fathead minnows (Pimephales promelas). 2005 Neurotoxicology pmid:15527869
Di S et al. Activity-dependent release and actions of endocannabinoids in the rat hypothalamic supraoptic nucleus. 2005 J. Physiol. (Lond.) pmid:16239276
Cabranes A et al. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. 2005 Neurobiol. Dis. pmid:16242629
McPartland JM et al. Cannabimimetic effects of osteopathic manipulative treatment. 2005 J Am Osteopath Assoc pmid:16118355
Wahn H et al. The endocannabinoid arachidonyl ethanolamide (anandamide) increases pulmonary arterial pressure via cyclooxygenase-2 products in isolated rabbit lungs. 2005 Am. J. Physiol. Heart Circ. Physiol. pmid:16055511